The Model of Excellence™
3D in vitro models empowering researchers to fuel a new era of breakthrough therapies
Promising Tool for MASH Drug Discovery Unveiled
InSphero's Liver Disease team has published a groundbreaking peer-reviewed paper in Nature's Scientific Reports, challenging the limitations of in vitro models in MASH Drug Discovery.
3D In Vitro Models and Solutions for Drug Safety & Efficacy
Liver Safety
Liver Disease
Islet Biology
Oncology & Immunology
3D Cell Culture Tools
Why 3D In Vitro with InSphero?
We are challenging the status quo, enabling the transition to alternatives to animal testing, and working to make human tissue 3D in vitro models accessible to researchers everywhere.
We empower scientists to reach their full potential in the quest for breakthrough therapies, through reliable, scalable, and reproducible
3D cell culture models, products, and services.
InSphero InSpires!
We are Reliable
Our customers count on our reliable and reproducible
3D in vitro models which reflect closely the human biology and enable informed preclinical stage decisions.
We are Scalable
We are the only 3D in vitro technology company providing up to 384 uniform cell culture models in an automation-compatible plate format ready for industry application.
We Deliver Quality
We remove the obstacles to 3D in vitro drug testing through a high uniformity of size, shape, cell composition, and count of our 3D models - well to well, batch to batch. For data consistency that impresses.
We are The Model of Excellence™
We set gold standards in industry-ready 3D in vitro models and technologies.
We do more than raise the bar for drug discovery: we reimagine what is possible!
InSphero 3D In Vitro Technology
Unlock the Full Potential of 3D In Vitro Drug Development with True...
Scalability ● Reproducibility ● Reliability
"Addressing complex diseases requires the rare combination of pioneering innovation and biomedical expertise. As our discovery partner, InSphero gives us immediate access to new 3D cell culture in vitro technologies, such as organ-on-a-chip systems, that provide deep mechanistic insights into complex diseases. They have become part of our research team, committed to helping us find a cure for Type 1 Diabetes.”
"Working with InSphero has been a great experience for us. As the Quris-AI BioAI platform is the first to simulate clinical trials and a real human body’s reaction to drugs, finding the right partner was no easy task. Every member of the InSphero team goes above and beyond to support our evolving 3D cell culture needs. Deepening our trust over the years, the company has consistently proven its dedication to transparency and diligent quality control efforts. Thanks to our continued collaboration with InSphero, Quris-AI has reliable access to the high-quality products needed to power our platform so we can predict which drugs will work safely in humans before clinical trials."
"Akura™ Plates have allowed Mosa Meat to automate our optimization of 3D cell cultures for the production of clean meat. We perform media exchanges, compound screenings, and stainings in an automated fashion using 96 and 384 Akura™ plates without the fear of sucking up our spheroids. The ease of implementation on our automation systems and the ease of use makes both our engineers and scientists happy."
About Us
InSphero is the only 3D in vitro models company with the platform and expertise to modernize drug discovery in a way that empowers researchers to reach their full potential.
Our innovative spheroid-based models allow for more effective, safe therapies to reach the clinic through truly superior robustness, reliability, reproducibility and scalability.
InSphero’s goal is to inspire the next generation of breakthrough therapies through customer centricity, commitment to innovation, and
The Model of Excellence™.
InSphero Blog
The Model of Excellence in 3D Cell Culture Research:
Scalable, Reliable, and Reproducible
News
InSphero and PharmaNest Unveil a Promising Tool for MASH Drug Discovery in a Breakthrough Study
nSphero's Liver Disease team has published a groundbreaking peer-reviewed paper in Nature's Scientific Reports, challenging the limitations of MASH Drug Discovery.
InSphero Strengthens its Executive Team by Appointing Paul Clémençon, MBA as Chief Business Officer
InSphero, the global leader in 3D in vitro technology for drug safety and efficacy testing, is proud to announce the appointment of Paul Clémençon, MBA as the new Chief Business Officer (CBO), further strengthening its Executive team.